Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EC3H
|
|||
| Drug Name |
Quinazoline derivative 12
|
|||
| Synonyms |
PMID26936077-Compound-23
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Patented | [1] | |
| Cirrhosis [ICD-11: DB93] | Patented | [1] | ||
| Gastrointestinal disease [ICD-11: DE2Z] | Patented | [1] | ||
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Patented | [1] | ||
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Patented | [1] | ||
| Company |
NeoPharm Co. Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16BrN3O3
|
|||
| Canonical SMILES |
COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4CC4
|
|||
| InChI |
1S/C19H16BrN3O3/c1-26-12-8-9-15(20)14(10-12)18(24)22-23-17(11-6-7-11)21-16-5-3-2-4-13(16)19(23)25/h2-5,8-11H,6-7H2,1H3,(H,22,24)
|
|||
| InChIKey |
OWJRZOOAIAWSHE-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteinase activated receptor 2 (PAR2) | Target Info | Antagonist | [1] |
| Target's Patent Info | Proteinase activated receptor 2 (PAR2) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| African trypanosomiasis | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.